Apollo Hospitals Enterprise Limited is India's largest integrated healthcare company — operating 70+ hospitals across India and overseas (Colombo, Dhaka, Mauritius) with 10,000+ licensed beds, a network of 6,000+ Apollo Pharmacy retail outlets, Apollo HealthCo diagnostics centres, and an ambitious digital health platform (Apollo 24|7) targeting 100 million registered users. Apollo is a Nifty 50 constituent and the most widely held healthcare stock in Indian institutional portfolios — but it is also one of the most complex to analyse, because it is simultaneously a mature hospital operator, a high-growth pharmacy retailer, and an early-stage digital health company, all within the same listed entity. Each of these three businesses has different economics, different growth stages, and deserves a different valuation multiple — making Apollo fundamentally a sum-of-parts story dressed as a single company.
The Core Hospital Business: EBITDA Per Bed as the Governing Metric
Apollo's hospital business economics are governed by three interlocking metrics: Average Revenue Per Occupied Bed (ARPOB), Occupancy Rate, and EBITDA Per Bed. ARPOB is the daily revenue earned from each occupied bed — driven by case mix (complex tertiary and quaternary procedures earn far more per day than routine admissions), payer mix (international patients and corporate health insurance payers earn higher ARPOB than government health scheme patients), and geography (South India hospitals, led by Hyderabad and Chennai, command premium ARPOB because of their quaternary care specialisation). Apollo's ARPOB of ₹60,000-75,000 per day compares to industry average of ₹35,000-45,000, reflecting Apollo's deliberate specialisation in oncology, cardiac care, organ transplantation, and neurology — procedures that command 2-5x premium over general medicine admissions. Occupancy Rate — beds occupied as a percentage of licensed capacity — drives the operating leverage in Apollo's business model. A hospital with 500 licensed beds and ₹200 crore of annual fixed costs (staff salaries, facility maintenance, equipment depreciation) needs 55-60% occupancy to break even at EBITDA level. At 70-75% occupancy — Apollo's mature hospital average — the same ₹200 crore fixed cost base generates ₹150-200 crore of EBITDA because every additional admission flows through at 70-80% incremental margin. This operating leverage is why Apollo's EBITDA margins (17-20% on hospital revenues) are substantially higher than the 8-12% typical for newer hospital chains at lower occupancy. EBITDA Per Bed is therefore the composite indicator — it captures both ARPOB quality and occupancy utilisation simultaneously. Apollo's mature hospitals (Chennai, Hyderabad, Delhi Indraprastha) generate ₹18-25 lakh EBITDA per bed per year. A greenfield Apollo hospital in a new city starts at ₹2-5 lakh EBITDA per bed and takes 7-10 years to approach this level. Use the BBS Stock Scorecard on Apollo — the ROCE of 12-16% (blended across mature and new hospitals) masks the >25% ROCE of the mature hospital cluster and the negative ROCE of recently commissioned hospitals in ramp-up. Stripping out the capex-heavy new hospitals and valuing the mature cluster separately is the correct analytical approach. Our annual report reading guide shows exactly how to locate ARPOB, occupancy, and per-hospital EBITDA breakdowns in Apollo's detailed segment disclosures.
- Hospitals: 70+ facilities, 10,000+ licensed beds across India and overseas
- Mature hospital ARPOB: ₹60,000-75,000 per day (tertiary/quaternary specialisation)
- Mature hospital occupancy: 70-75% (industry: 55-65%)
- Mature hospital EBITDA margin: 17-20% on revenues
- Mature hospital EBITDA per bed: ₹18-25 lakh per year
- Apollo Pharmacy outlets: 6,000+ (second only to generic pharmacy chains)
- Apollo HealthCo (AHLL) entity: pharmacy + diagnostics, separately listed subsidiary
- Apollo 24|7 digital health app: 30+ million registered users
- Total revenue FY25: ~₹20,000-22,000 crore (consolidated)
- Total EBITDA FY25: ~₹3,500-4,200 crore (blended, all segments)
- Market cap: ~₹90,000-1,00,000 crore
The Brownfield vs Greenfield Expansion Cycle
Apollo's capex and growth story divides cleanly into brownfield (adding beds to existing hospital sites) and greenfield (new hospital builds on new land). Brownfield expansion is the preferred route — existing hospitals have existing brand equity, doctor relationships, referral networks, and support infrastructure (labs, radiology, pharmacy) that a new hospital must build from zero. Adding 200 beds to Apollo Chennai's existing campus costs ₹400-600 crore but those beds hit EBITDA breakeven within 18-24 months because they inherit the parent hospital's ARPOB, occupancy culture, and patient flow. The capital efficiency on brownfield beds is dramatically higher — ROIC reaches 18-25% within 3-4 years. Greenfield builds are necessary for geographic expansion (entering new cities where Apollo has no presence) but carry higher risk. A ₹600-800 crore greenfield hospital in a Tier 2 city requires 4-5 years to reach 60% occupancy, and 7-10 years to generate ROCE above WACC. The risk: if the local competitive dynamics shift (a government hospital expands, a competing private chain enters), the occupancy ramp stalls. Apollo's management has become progressively more disciplined about greenfield deployment since the capital-intensive FY15-20 expansion cycle created earnings pressure from high depreciation on immature hospitals. The current strategy: 60-70% of new beds are brownfield (lower risk, faster ROIC), with greenfield deployments focused on cities where Apollo has a clear referral advantage (near Apollo educational institutions, medical colleges, or Apollo Clinic network). The Apollo Proton Cancer Centre (APCC) in Chennai is a stand-alone example of high-risk/high-reward greenfield: the only proton therapy facility in South Asia, with a ₹1,500+ crore total investment, targeting cancer patients from Southeast Asia, Middle East, and Africa who otherwise travel to the US or Germany for proton treatment. At full utilisation (60+ patients per day), APCC could generate ₹800-1,000 crore revenue at 40%+ EBITDA margin — making it a ₹300-400 crore EBITDA contributor at maturity. It is currently in ramp-up and is the primary reason Apollo's consolidated ROCE looks subdued relative to the mature hospital cluster's economics. Use the BBS PE Analyser on Apollo — the blended consolidated PE of 45-60x is high, but when you strip out the digital health losses and APCC ramp-up drag, the mature hospital cluster PE is closer to 30-35x on a through-cycle basis — reasonable for a healthcare compounder growing EBITDA at 18-22% per year. Read our Oberoi Realty analysis for the same brownfield vs greenfield framework applied to real estate — the capital allocation logic is nearly identical.
AHLL and Apollo HealthCo: The Pharmacy + Diagnostics Business
Apollo HealthCo Limited (AHLL) is a separately listed subsidiary of Apollo Hospitals (Apollo Hospitals holds ~67% stake), combining Apollo Pharmacy's 6,000+ retail outlets and Apollo Diagnostics' 700+ diagnostic centres. AHLL went public in FY22 and is one of the largest listed pharmacy retail companies in India. The strategic logic of AHLL: healthcare is a continuum — a patient interacts with a pharmacy more frequently than with a hospital. Apollo Pharmacy captures this day-to-day health interaction and creates multiple revenue streams: prescription fulfilment (highest volume, lowest margin), OTC products (moderate margin), Apollo-branded nutraceuticals and wellness products (highest margin, growing), and insurance and diagnostic referrals (fee-based, capital-light). Apollo Pharmacy's competitive advantage: trust inheritance from the Apollo hospital brand, access to Apollo's hospital catchment area patients (a patient discharged from Apollo Chennai will default to the Apollo Pharmacy next to the hospital), and the ability to sell higher-margin branded generics and wellness products using the Apollo brand name. Apollo Diagnostics competes with Dr Lal PathLabs, Metropolis, and SRL in a fragmented market — the differentiator is integration with Apollo hospitals (referral flow, integrated medical records) and the Apollo 24|7 platform (home sample collection, teleconsultation-to-test integration). AHLL's consolidated financials (pharmacy + diagnostics combined) show revenue of ₹7,000-8,500 crore and EBITDA of ₹350-500 crore — EBITDA margins of 4-6% reflect the low-margin pharmacy retail business dominating the mix. As diagnostics grows (which carries 20-25% EBITDA margin), AHLL's blended margins should improve toward 8-10% by FY28. The listed subsidiary discount: AHLL trades at a market cap of ₹25,000-35,000 crore — implying the 67% stake Apollo Hospitals holds is worth ₹17,000-23,000 crore. For consolidated Apollo Hospitals valuation, this AHLL stake is a separate, partially-liquid asset that should be valued independently and subtracted from the holding company's consolidated EV before applying a hospital-sector EV/EBITDA multiple to the standalone hospital EBITDA. Run the BBS Red Flag Detector on AHLL separately — check for pharmacy retail's thin EBITDA margins, working capital cycle (pharmacy retail requires significant inventory), and whether OCF is consistently positive despite heavy store rollout capex.
Apollo 24|7: The Digital Health Bet and How to Value It
Apollo's most ambitious initiative — and its most controversial from a valuation perspective — is Apollo 24|7, a super-app combining teleconsultation (video + chat consultations with Apollo doctors), pharmacy delivery (integrated with Apollo Pharmacy inventory), diagnostic test booking (home sample collection), chronic disease management programs, and preventive health packages. Apollo 24|7 had 30+ million registered users and approximately 3-5 million monthly active users by FY25. The bull case: Apollo 24|7 is building the infrastructure to monetise Apollo's brand with 500 million+ Indians who will never walk into an Apollo hospital but will consult an Apollo doctor via video for ₹200-500 per consultation. If Apollo 24|7 achieves 20 million monthly active users with ₹1,200 average annual revenue per user (teleconsultation + pharmacy GMV + diagnostics), it could generate ₹24,000 crore GMV — with pharmacy take-rate of 15% and teleconsultation revenue 100%, this implies ₹4,000-6,000 crore in revenue at the mature state. At the early-stage digital health comparable (2-3x revenue), this is a ₹8,000-18,000 crore valuation. The bear case: healthcare super-apps have been capital graveyards globally (Amazon Care shut down, Babylon Health collapsed, Ping An Good Doctor in China trades at a fraction of its IPO valuation). Teleconsultation in India faces the cultural barrier of patients preferring in-person consultations for anything beyond basic cold/cough symptoms, doctor resistance to platform-mediated consultations (fear of commoditisation), and the genuine medical-legal risk of misdiagnosis in a low-information video setting. Apollo 24|7 currently loses money — the digital health segment's EBITDA loss of ₹200-400 crore per year is visible in Apollo's segment disclosures. BBS assessment: the digital health business has optionality value — material if it succeeds, bounded downside since the core hospital and pharmacy businesses underpin the stock regardless. At current prices, investors are paying approximately 1x revenue for the digital health optionality embedded in Apollo's consolidated valuation. That is a reasonable price to pay for the option — but investors should not assign high-conviction valuations to a segment where comparable global companies have serially underdelivered. Enrol in the BBS healthcare sector course for the complete sum-of-parts modelling framework for Apollo — the course builds separate DCF and EV/EBITDA models for the mature hospital cluster, AHLL pharmacy + diagnostics, and Apollo 24|7 digital, then combines them into a consolidated valuation range with scenario analysis.
🔍 BBS Insight
Apollo's quarterly results have one number BBS prioritises above all others: Mature Hospital EBITDA Per Bed (disclosed in the hospital segment investor presentation, available on the Apollo Hospitals Investor Relations page quarterly). In mature hospitals (Chennai, Hyderabad, Delhi IP, Kolkata), EBITDA per bed above ₹20 lakh per year signals sustained pricing power and occupancy quality. A decline in this metric — even if total EBITDA grows — signals either occupancy pressure (beds sitting idle in the mature cluster despite high capex) or case mix deterioration (shift toward lower-acuity, lower-ARPOB admissions). The second metric: AHLL pharmacy same-store sales growth (SSSG). If AHLL pharmacy SSSG is above 10% consistently, the pharmacy business is gaining share organically — not just by store addition. Below 8% SSSG signals either competition intensification (Reliance Retail Pharmacy, Tata 1mg) or Apollo Pharmacy's inability to differentiate on product mix. The third: Apollo 24|7 monthly active users (disclosed in annual reports and some investor presentations). The trajectory from 3 million to 10 million+ monthly active users, if achieved in the next 3 years, would justify re-rating the digital health segment from minimal value to ₹10,000-15,000 crore. All three metrics together determine whether Apollo at 45-55x consolidated earnings is genuinely expensive or correctly priced for a business compounding EBITDA at 18-22% with a growing sum-of-parts.